CA2658327C - Compound that can inhibit ubc13-uev interactions, pharmaceutical compositions and therapeutic uses - Google Patents

Compound that can inhibit ubc13-uev interactions, pharmaceutical compositions and therapeutic uses Download PDF

Info

Publication number
CA2658327C
CA2658327C CA2658327A CA2658327A CA2658327C CA 2658327 C CA2658327 C CA 2658327C CA 2658327 A CA2658327 A CA 2658327A CA 2658327 A CA2658327 A CA 2658327A CA 2658327 C CA2658327 C CA 2658327C
Authority
CA
Canada
Prior art keywords
substituted
unsubstituted
ethyl
solvate
stereoisomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2658327A
Other languages
English (en)
French (fr)
Other versions
CA2658327A1 (en
Inventor
Timothy Thomson Okatsu
Johanna Scheper Sigmund
Angel Messeguer Peypoch
Angel Ramirez Ortiz
Gloria Sanclimens Perez De Rozas
Isabel Masip Masip
Alejandra Moure Fernandez
Domingo Gonzalez Ruiz
Antonio Morreale De Leon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Consejo Superior de Investigaciones Científicas
Original Assignee
Consejo Superior de Investigaciones Científicas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Superior de Investigaciones Científicas filed Critical Consejo Superior de Investigaciones Científicas
Publication of CA2658327A1 publication Critical patent/CA2658327A1/en
Application granted granted Critical
Publication of CA2658327C publication Critical patent/CA2658327C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2658327A 2006-07-20 2007-03-07 Compound that can inhibit ubc13-uev interactions, pharmaceutical compositions and therapeutic uses Expired - Fee Related CA2658327C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ESP200601933 2006-07-20
ES200601933A ES2293834B1 (es) 2006-07-20 2006-07-20 Compuesto con actividad inhibidora de las interacciones ubc13-uev, composiciones farmaceuticas que lo comprenden y sus aplicaciones terapeuticas.
PCT/ES2007/000120 WO2008009758A1 (es) 2006-07-20 2007-03-07 Compuestos con actividad inhibidora de las interacciones ubc13-uev, composiciones farmacéuticas y aplicaciones terapéuticas

Publications (2)

Publication Number Publication Date
CA2658327A1 CA2658327A1 (en) 2008-01-24
CA2658327C true CA2658327C (en) 2013-12-03

Family

ID=38956569

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2658327A Expired - Fee Related CA2658327C (en) 2006-07-20 2007-03-07 Compound that can inhibit ubc13-uev interactions, pharmaceutical compositions and therapeutic uses

Country Status (9)

Country Link
US (2) US8252786B2 (enExample)
EP (1) EP2045251B1 (enExample)
JP (1) JP5203363B2 (enExample)
CN (1) CN101506196B (enExample)
AU (1) AU2007275073B2 (enExample)
CA (1) CA2658327C (enExample)
ES (1) ES2293834B1 (enExample)
MX (1) MX2009000672A (enExample)
WO (1) WO2008009758A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006138380A2 (en) 2005-06-15 2006-12-28 Massachusetts Institute Of Technology Amine-containing lipids and uses thereof
WO2010053572A2 (en) 2008-11-07 2010-05-14 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
CA2769408C (en) * 2009-07-30 2017-09-05 Laboratorios Salvat, S.A. Apaf-1 inhibitor compounds
SI2506857T1 (en) 2009-12-01 2018-08-31 Translate Bio, Inc. Delivery of mRNA for the enrichment of proteins and enzymes in human genetic diseases
US9193827B2 (en) 2010-08-26 2015-11-24 Massachusetts Institute Of Technology Poly(beta-amino alcohols), their preparation, and uses thereof
US20130345231A1 (en) * 2011-03-23 2013-12-26 Indiana University Research And Technology Corporation Anticancer therapeutic agents
CA2831392C (en) 2011-03-28 2020-04-28 Massachusetts Institute Of Technology Conjugated lipomers and uses thereof
KR20220025112A (ko) 2011-06-08 2022-03-03 샤이어 휴먼 지네틱 테라피즈 인크. Mrna 전달을 위한 지질 나노입자 조성물 및 방법
US9512073B2 (en) 2011-10-27 2016-12-06 Massachusetts Institute Of Technology Amino acid-, peptide-and polypeptide-lipids, isomers, compositions, and uses thereof
US20130236504A1 (en) * 2012-03-06 2013-09-12 Medical University Of South Carolina Delivery System for Enhancing Drug Efficacy
EP3536787A1 (en) 2012-06-08 2019-09-11 Translate Bio, Inc. Nuclease resistant polynucleotides and uses thereof
WO2014028487A1 (en) 2012-08-13 2014-02-20 Massachusetts Institute Of Technology Amine-containing lipidoids and uses thereof
EA201591229A1 (ru) 2013-03-14 2016-01-29 Шир Хьюман Дженетик Терапис, Инк. Способы очистки матричной рнк
KR102311614B1 (ko) 2013-03-14 2021-10-08 샤이어 휴먼 지네틱 테라피즈 인크. Cftr mrna 조성물 및 관련 방법 및 사용
US9315472B2 (en) 2013-05-01 2016-04-19 Massachusetts Institute Of Technology 1,3,5-triazinane-2,4,6-trione derivatives and uses thereof
EP3574923A1 (en) 2013-10-22 2019-12-04 Translate Bio, Inc. Mrna therapy for phenylketonuria
ES3032935T3 (en) 2013-10-22 2025-07-29 Translate Bio Inc Lipid formulations for delivery of messenger rna
ES2707966T3 (es) 2013-10-22 2019-04-08 Translate Bio Inc Terapia de ARNm para la deficiencia en síntesis de argininosuccinato
JP6295767B2 (ja) 2014-03-25 2018-03-20 富士通株式会社 スイッチ装置、情報処理システムおよびスイッチ装置の制御方法
EP4729528A3 (en) 2014-04-25 2026-06-24 Translate Bio, Inc. Methods for purification of messenger rna
WO2015184256A2 (en) 2014-05-30 2015-12-03 Shire Human Genetic Therapies, Inc. Biodegradable lipids for delivery of nucleic acids
KR102559979B1 (ko) 2014-06-24 2023-07-25 샤이어 휴먼 지네틱 테라피즈 인크. 핵산의 전달용 입체화학적으로 풍부한 조성물
WO2016004202A1 (en) 2014-07-02 2016-01-07 Massachusetts Institute Of Technology Polyamine-fatty acid derived lipidoids and uses thereof
RS64331B1 (sr) 2015-06-19 2023-08-31 Massachusetts Inst Technology Alkenil supstituisani 2,5-piperazindioni i njihova primena u sastavima za isporuku agensa u organizam ili ćeliju subjekta
MX2019010155A (es) 2017-02-27 2020-12-10 Translate Bio Inc Arnm de cftr optimizado por codón novedoso.
IL270631B2 (en) 2017-05-16 2024-03-01 Translate Bio Inc Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr
US11174500B2 (en) 2018-08-24 2021-11-16 Translate Bio, Inc. Methods for purification of messenger RNA
AU2019384557B2 (en) 2018-11-21 2025-07-17 Translate Bio, Inc. Treatment of cystic fibrosis by delivery of nebulized mRNA encoding CFTR
WO2020252487A1 (en) * 2019-06-14 2020-12-17 Children's Hospital Medical Center Rational therapeutic targeting of oncogenic immune signaling states in myeloid malignancies via the ubiquitin conjugating enzyme ube2n
CA3155003A1 (en) 2019-09-20 2021-03-25 Translate Bio, Inc. Mrna encoding engineered cftr
KR102977795B1 (ko) 2020-08-04 2026-06-15 삼성전자주식회사 홈 화면을 복원하는 방법 및 이를 적용한 전자 장치
WO2023225277A1 (en) * 2022-05-19 2023-11-23 Ohio State Innovation Foundation Peptidyl flavor modifiers

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4234295A1 (de) * 1992-10-12 1994-04-14 Thomae Gmbh Dr K Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US6271199B2 (en) * 1997-02-15 2001-08-07 Millennium Pharmaceuticals, Inc. Treatment of infarcts
WO2002011750A2 (en) * 2000-08-08 2002-02-14 The Government Of The United States Of America, As Represented By The Secretary Of Health And Human Prevention of beta-amyloid neurotoxicity by blockade of the ubiquitin-proteasome proteolytic pathway
ES2169690B1 (es) * 2000-10-06 2004-03-16 Diverdrugs Sl Trimeros de n-alquilglicina capaces de proteger a neuronas contra agresiones excitotoxicas, y composiciones que los contienen.
TW200538149A (en) 2004-05-20 2005-12-01 Telik Inc Sensitization to another anticancer therapy and/or amelioration of a side effect of another anticancer therapy by treatment with a GST-activated anticancer compound
ES2296484B1 (es) * 2005-11-23 2009-04-01 Fundacion De La Comunidad Valenciana Centro De Investigacion Principe Felipe (90%) Composicion farmaceutica para inhibir la apoptosis.

Also Published As

Publication number Publication date
CN101506196A (zh) 2009-08-12
US8785430B2 (en) 2014-07-22
US20110160189A1 (en) 2011-06-30
WO2008009758A1 (es) 2008-01-24
MX2009000672A (es) 2009-02-04
ES2293834A1 (es) 2008-03-16
CA2658327A1 (en) 2008-01-24
JP2009544600A (ja) 2009-12-17
EP2045251B1 (en) 2015-11-18
EP2045251A1 (en) 2009-04-08
US8252786B2 (en) 2012-08-28
ES2293834B1 (es) 2009-02-16
AU2007275073A1 (en) 2008-01-24
CN101506196B (zh) 2013-11-20
AU2007275073B2 (en) 2012-06-07
EP2045251A4 (en) 2010-12-01
US20130237529A1 (en) 2013-09-12
JP5203363B2 (ja) 2013-06-05

Similar Documents

Publication Publication Date Title
AU2007275073B2 (en) Compound that can inhibit UBC13-UEV interactions, pharmaceutical compositions and therapeutic uses
US20220387602A1 (en) Bifunctional degraders and their methods of use
US20210283261A1 (en) Compositions and Methods for Treating ALK-Mediated Cancer
US10259809B2 (en) Fluorinated imidazo[4,5-C]quinoline derivatives as inhibitors of bromodomain containing proteins
WO2017024317A2 (en) Methods to induce targeted protein degradation through bifunctional molecules
US20200087314A1 (en) Histone deacetylase inhibitors
DE69412467T2 (de) Ungesättigte aminoverbindungen zur verwendung als antikrebsmittel und als mittelgegen protozoen
US20190084973A1 (en) Read-through compound prodrugs suppressing premature nonsense mutations
Chu et al. Synthesis and biological evaluation of C-4 substituted phenoxazine-bearing hydroxamic acids with potent class II histone deacetylase inhibitory activities
EP1846366B1 (en) Norvaline derivative and method for preparation thereof
Zadorozhnii et al. Synthesis of (Z)-N, 3-dicyclohexyl-6-substituted-4-(trichloromethyl)-3, 4-dihydro-2H-1, 3, 5-oxadiazin-2-imines via [4+ 2] hetero Diels-Alder reaction: Their spectral characteristics and molecular structure
US6160118A (en) Process for the synthesis of substituted piperazinones via Mitsunobu reaction
Weck et al. Does the exception prove the rule? A comparative study of supramolecular synthons in a series of lactam esters
Fesenko et al. New synthesis of β-(4-semicarbazido) carboxylic acid-based peptidomimetics and 3-amino-5, 6-dihydrouracils via an amidoalkylation protocol
Caleb et al. Synthesis and ESI-MS/MS Fragmentation Study of Two New Isomeric Oxazolidin-2-One Derivatives
Obniska et al. Synthesis, physicochemical and anticonvulsant properties of new N-4-arylpiperazin-1-yl amides of (2-aza-1, 3-dioxospiro [4, 5] dec-2-yl)-acetic acid
Nesterkina et al. Synthesis and Anticonvulsant Activity of New Calix [4] Arene Derivatives Containing Gamma-Aminobutyric Acid Moieties
WO2000001678A1 (en) Process for the synthesis of substituted piperazinones via mitsunobu reaction
Tkachenko et al. Month 2018 Grignard Reagents and Their N-analogues in the Synthesis of Tricyclic and Tetracyclic Cage-like Lactams
Beagle Innovative strategies for the synthesis of heterocycles of potential interest in medicinal chemistry
US7678784B2 (en) Oxime-containing macrocyclic acyl guanidines as β-secretase inhibitors
Beconi et al. Oral Administration of the Pimelic Diphenylamide HDAC Inhibitor HDACi 4b Is
HK1253036A1 (en) Oxime compounds as agonists of the muscarinic m1 and/or m4 receptor

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20170307